MTR 2756 A > G polymorphism is associated with the risk of systemic lupus erythematosus in the Polish population

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by overexpression of cytokines and T cell accessory molecules, which is due to a reduction of DNA regulatory region methylation in T cells. It has been shown that polymorphic variants of genes encoding key enzymes of folate and methionine metabolism may have an effect on DNA methylation. Therefore, in patients with SLE (n = 106) and controls (n = 141) we examined the distribution of polymorphisms of genes encoding methionine synthase (MTR); 5,10-methylenetetrahydrofolate dehydrogenase, 5,10-methenyltetrahydrofolate cyclohydrolase and 10-formyltetrahydrofolate synthetase (MTHFD1); and methylenetetrahydrofolate reductase (MTHFR). We found that MTR 2756AG (919DG) or GG (919GG) genotype exhibited 2.005-fold increased risk of SLE (95% CI = 1.177—3.416, P = 0.0146). However, MTHFR 677C > T (A222V) and MTHFD1 1958G > A (R653Q) allele and genotype frequencies did not exhibit statistical differences between SLE patients and controls. Since MTR is located on 1q43, our findings confirm the significance of the role of 1q region and the methyl cycle in etiopathogenesis of SLE. Lupus (2007) 16, 450—454.

Keywords

MTHFD1 MTHFR MTR polymorphisms SLE

Get full access to this article

View all access options for this article.

References

Tan EM , Cohen AS , Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271—1277.

Bombardier C. , Gladman DD , Urowitz MB , Caron D. , Chang CH Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630—640.

Dayal AK , Kammer GM The T cell enigma in lupus. Arthritis Rheum 1996; 39: 23—33.

Wilson CB , Makar KW , Perez-Melgosa M. Epigenetic regulation of T cell fate and function. J Infect Dis 2002; 185: 37—45.

Makers KW , Wilson CB DNA methylation is a nonredundant repressor of the Th2 effector program . J Immunol 2004; 173: 4402—4406.

Fuks F. , Burgers WA , Brehm A. , Hughes-Davies L. , Kouzarides T. DNA methyltransferase Dnmt1 associates with histone deacetylase activity . Nat Genet 2000; 20: 88—91.

Robertson KD , Uzvolgyi E. , Liang G. et al. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res 1999; 27: 2291—2298.

Cantoni GL

The role of S-adenosylhomocysteine in the biological utilization of S-adenosylmethionine. Prig Clin

Biol Res 1985 ; 198: 47—65.

Hoffman DR , Cornatzer WE , Duerre JA Relationship between tissue levels of S-adenosylmethionine, S-adenylhomocysteine, and trans-methylation reactions. Can J Biochem 1979; 57: 56—65.

10.

Cantoni GL S-adenosylmethionine; a new intermediate fordem enzymatically from L-methionine and adenosinetriphosphate. J Biol Chem 1953 ; 204: 403—416.

11.

Arakawa T. , Narisawa K. , Tanno K. , Hirooka Y. , Ono T. Megaloblastic anemia and mental retardation associated with hyperfolic-acidemia: probably due to N-5-methyltetrahydrofolate transferase deficiency. Tohoku J Exp Med 1967; 93: 1—22.

12.

Frosst P. , Blom HJ , Milos R. et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genet 1995; 10: 111—113.

13.

Hum DW , Bell AW , Rozen R. , MacKenzie RE. Primary structure of a human trifunctional enzyme: isolation of a cDNA encoding methylenetetrahydrofolate-dehydrogenase, methenyltetrahydrofolatecyclohydrolase, formyltetrahydrofolate synthetase. J Biol Chem 1988; 263: 15946—15950.

14.

Ballestar E. , Esteller M. , Richardson BC The epigenetic face of systemic lupus erythematosus . J Immunol 2006; 176: 7143—7143.

15.

Chen LH , Liu ML , Hwang HY , Chen LS , Korenberg J. , Shane B. Human methionine synthase: cDNA cloning, gene localization, and expression . J Biol Chem 1997; 272: 3628—3634.

16.

Paz MF , Avila S. , Fraga MF et al. Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors. Cancer Res 2002; 62: 4519—4524.

17.

James SJ , Melnyk S. , Pogribna M. , Pogribny IP , Caudill MA Elevation in S-adenosylhomocysteine and DNA hypomethylation: potential epigenetic mechanism for homocysteine-related pathology. J Nutr 2002; 132: 2361S—2366S.

18.

Brody LC , Conley M. , Cox C. et al. A polymorphism, R653Q, in the trifunctional enzyme methylenetetrahydrofolate dehydrogenase/ methenyltetrahydrofolate cyclohydrolase/formyltetrahydrofolate synthetase is a maternal genetic risk factor for neural tube defects: report of the Birth Defects Research Group. Am J Hum Genet 2002; 71: 1207—1215.

19.

Parle-McDermott A. , Mills JL , Kirke PN et al. MTHFD1 R653Q polymorphism is a maternal genetic risk factor for severe abruptio placentae . Am J Med Genet A 2005; 132: 365—368.

20.

Hol FA , van der Put NM , Geurds MP et al. Molecular genetic analysis of the gene encoding the trifunctional enzyme MTHFD (methylenetetrahydrofolate-dehydrogenase, methenyltetrahydrofolate-cyclohydrolase, formyltetrahydrofolate synthetase) in patients with neural tube defects. Clin Genet 1998; 53: 119—125.

21.

Mostowska A. , Hozyasz KK , Jagodzinski PP Maternal MTR genotype contributes to the risk of non-syndromic cleft lip and palate in the Polish population. Clin Genet 2006; 69: 512—517.

22.

Doolin MT , Barbaux S. , McDonnell M. , Hoess K. , Whitehead AS , Mitchell LE Maternal genetic effects, exerted by genes involved in homocysteine remethylation, influence the risk of spina bifida. Am J Hum Genet 2002; 71: 1222—1226.

23.

Bosco P. , Gueant-Rodriguez RM , Anello G. et al. Methionine synthase (MTR) 2756 (A —> G) polymorphism, double heterozygosity methionine synthase 2756 AG/methionine synthase reductase (MTRR) AG, and elevated homocysteinemia are three risk factors for having a child with Down syndrome. Am J Med Genet A 2003; 121: 219—224.

24.

Fang JY , Xiao SD Folic acid, polymorphism of methyl-group metabolism genes, and DNA methylation in relation to GI carcinogenesis. J Gastroenterol 2003; 9: 821—829.

25.

Gemmati D. , Ongaro A. , Scapoli GL et al. Common gene polymorphisms in the metabolic folate and methylation pathway and the risk of acute lymphoblastic leukemia and non-Hodgkin's lymphoma in adults. Cancer Epidemiol Biomarkers Prev 2004; 5: 787—794.

26.

Skibola CF , Forrest MS , Coppede F. et al. Polymorphisms and haplotypes in folate-metabolizing genes and risk of non-Hodgkin lymphoma. Blood 2004; 7: 2155—2162.

27.

Harmon DL , Shields DC , Woodside JV et al. Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations. Genet Epidemiol 1999; 4: 298—309.

28.

Tsai MY , Bignell M. , Yang F. , Welge BG , Graham KJ , Hanson NQ Polygenic influence on plasma homocysteine: association of two prevalent mutations, the 844ins68 of cystathionine beta-synthase and A(2756)G of methionine synthase, with lowered plasma homocysteine levels. Atherosclerosis 2000; 1: 131—137.

29.

Chen J. , Stampfer MJ , Ma J. et al. Influence of a methionine synthase (D919G) polymorphism on plasma homocysteine and folate levels and relation to risk of myocardial infarction . Atherosclerosis 2001; 3: 667—672.

30.

Silaste ML , Rantala M. , Sampi M. , Alfthan G. , Aro A. , Kesaniemi YA Polymorphisms of key enzymes in homocysteine metabolism affect diet responsiveness of plasma homocysteine in healthy women. J Nutr 2001; 10: 2643—2647.

31.

Jones PA , Takai D. The role of DNA methylation in mammalian epigenetics. Science 2001; 5532: 1068—1070.

32.

Das PM , Singal R. DNA methylation and cancer. J Clin Oncol 2004 ; 22: 4632—4642.

33.

Kang S. , Kim JW , Kang GH et al. Polymorphism in folate- and methionine-metabolizing enzyme and aberrant CpG island hypermethylation in uterine cervical cancer. Gynecol Oncol 2005; 1: 173—180.

34.

Richardson BC , Strahler JR , Pivirotto TS et al. Phenotypic and functional similarities between 5-azacytidine-treated T cells and a T cell subset in patients with active systemic lupus erythematosus. Arthritis Rheum 1992; 35: 647—662.

35.

Sano H. , Takai O. , Harata N. , Yoshinaga K. , Kodama-Kamada I. , Sasaki T. Binding properties of human anti-DNA antibodies to cloned human DNA fragments . Scand J Immunol 1989; 30: 51—63.

36.

Yu D. , Zhu FG , Bhagat L. et al. Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties. Biochem Biophys Res Commun 2002; 297: 83—90.

37.

Wong M. , Tsao BP Current topics in human SLE genetics. Springer Semin Immunopathol Epub 2006; 28: 97—107.

38.

Meyer O. , Hauptmann G. , Tappeiner G. , Ochs HD , Mascart-Lemone F. Genetic deficiency of C4, C2 or C1q and lupus syndromes. Association with anti-Ro (SS-A) antibodies. Clin Exp Immunol 1985; 62: 678—684.

39.

Tsao BP , Cantor R. , Kalunian KC et al. Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus. J Clin Invest 1997; 99: 725—731.